Somatuline 120mg for s.c. Injection[acromegaly, pituitary gigantism] (ソマチュリン皮下注120mg［先端巨大症・下垂体性巨人症］) Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

somatuline 120mg for s.c. injection[acromegaly, pituitary gigantism] (ソマチュリン皮下注120mg［先端巨大症・下垂体性巨人症］)

teijin pharma limited - lanreotide acetate - injection

Somatuline 60mg for s.c. Injection [thyroid-stimulating hormone-secreting pituitary tumor] (ソマチュリン皮下注60mg［甲状腺刺激ホルモン産生下垂体腫瘍］) Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

somatuline 60mg for s.c. injection [thyroid-stimulating hormone-secreting pituitary tumor] (ソマチュリン皮下注60mg［甲状腺刺激ホルモン産生下垂体腫瘍］)

teijin pharma limited - lanreotide acetate - injection

Somatuline 60mg for s.c. Injection[acromegaly, pituitary gigantism] (ソマチュリン皮下注60mg［先端巨大症・下垂体性巨人症］) Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

somatuline 60mg for s.c. injection[acromegaly, pituitary gigantism] (ソマチュリン皮下注60mg［先端巨大症・下垂体性巨人症］)

teijin pharma limited - lanreotide acetate - injection

Somatuline 90mg for s.c. Injection [thyroid-stimulating hormone-secreting pituitary tumor] (ソマチュリン皮下注90mg［甲状腺刺激ホルモン産生下垂体腫瘍］) Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

somatuline 90mg for s.c. injection [thyroid-stimulating hormone-secreting pituitary tumor] (ソマチュリン皮下注90mg［甲状腺刺激ホルモン産生下垂体腫瘍］)

teijin pharma limited - lanreotide acetate - injection

Somatuline 90mg for s.c. Injection[acromegaly, pituitary gigantism] (ソマチュリン皮下注90mg［先端巨大症・下垂体性巨人症］) Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

somatuline 90mg for s.c. injection[acromegaly, pituitary gigantism] (ソマチュリン皮下注90mg［先端巨大症・下垂体性巨人症］)

teijin pharma limited - lanreotide acetate - injection

Mytolac New Zealand - English - Medsafe (Medicines Safety Authority)

mytolac

boucher & muir (new zealand) limited t/a bnm group - lanreotide acetate 27.3%{relative} equivalent to lanreotide 120 mg - solution for injection - 120 mg - active: lanreotide acetate 27.3%{relative} equivalent to lanreotide 120 mg excipient: acetic acid water for injection - indicated for: - the treatment of acromegaly when the circulating levels of growth hormone and igf-1 remain abnormal after surgery and/or radiotherapy or in patients who are dopamine agonist treatment refractory. - the treatment of symptoms of carcinoid syndrome associated with carcinoid tumours. - the treatment of well or moderately differentiated gastroenteropancreatic neuroendocrine tumours (gep-nets) in adult patients with unresectable locally advanced or metastatic disease.

Mytolac New Zealand - English - Medsafe (Medicines Safety Authority)

mytolac

boucher & muir (new zealand) limited t/a bnm group - lanreotide acetate 27.3%{relative} equivalent to lanreotide 60mg - solution for injection - 60 mg - active: lanreotide acetate 27.3%{relative} equivalent to lanreotide 60mg excipient: acetic acid water for injection - indicated for: - the treatment of acromegaly when the circulating levels of growth hormone and igf-1 remain abnormal after surgery and/or radiotherapy or in patients who are dopamine agonist treatment refractory. - the treatment of symptoms of carcinoid syndrome associated with carcinoid tumours. - the treatment of well or moderately differentiated gastroenteropancreatic neuroendocrine tumours (gep-nets) in adult patients with unresectable locally advanced or metastatic disease.

Mytolac New Zealand - English - Medsafe (Medicines Safety Authority)

mytolac

boucher & muir (new zealand) limited t/a bnm group - lanreotide acetate 27.3%{relative} equivalent to lanreotide 90 mg - solution for injection - 90 mg - active: lanreotide acetate 27.3%{relative} equivalent to lanreotide 90 mg excipient: acetic acid water for injection - indicated for: - the treatment of acromegaly when the circulating levels of growth hormone and igf-1 remain abnormal after surgery and/or radiotherapy or in patients who are dopamine agonist treatment refractory. - the treatment of symptoms of carcinoid syndrome associated with carcinoid tumours. - the treatment of well or moderately differentiated gastroenteropancreatic neuroendocrine tumours (gep-nets) in adult patients with unresectable locally advanced or metastatic disease.

CEDILANID Tablets Ireland - English - HPRA (Health Products Regulatory Authority)

cedilanid tablets

novartis pharmaceuticals uk ltd - lanatoside c - tablets

Paracetamol 500mg capsules United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

paracetamol 500mg capsules

bristol laboratories ltd - paracetamol - oral capsule - 500mg